---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-26-000047"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2026-09-08T20:01:51+00:00"
generated_at: "2026-09-08T20:03:20.766680+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inhibrx INBRX-106 nearly doubles cORR in Phase 2 HNSCC; PFS 9.6 vs 4.9 months

## Summary
- cORR 48.3% (INBRX-106+pembro) vs 26.5% (pembro alone); CR 13.8% vs 0%.
- Median PFS 9.6 vs 4.9 months; 6-mo PFS 72.4% vs 42.8%.
- HPV+ subgroup: cORR 80% vs 33.3%, CR 30% vs 0%, PFS6 90% vs 33%.
- Plans to expand Phase 2 by ~50 HPV+ OPSCC patients; Phase 3 as confirmatory.
- Combination manageable; common AEs rash, fatigue, diarrhea (low grade).

## SEC filing metadata
- accession: 0002007919-26-000047
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2026-09-08T20:01:51+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/0002007919-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/inhibrx-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-26-000047
- JSON: https://secwatch.observer/filing/0002007919-26-000047.json
- Plain text: https://secwatch.observer/filing/0002007919-26-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.